RAC1 and gastric cancer: MiR-345 directly targets epidermal growth factor receptor pathway substrate 8 (EPS8), which leads to the inactivation of Rac1 and inhibits cell migration, EMT, and the cancer stem cell phenotype, thereby suppressing gastric cancer metastasis [130].